Inspired by XBP - 1's roles in maintaining a homeostatic ER, the lab began to examine the role of XBP - 1 in B -
cell leukemia whose progression does not require dramatic ER expansion like that in multiple myeloma.
Not exact matches
By creating an experimental model of
leukemia in mice
whose cancer
cells were resistant to chemotherapy the team was able to caracterize these
cells» metabolic profile and observed certain modifications at the level of the mitochondria.
Park and colleagues genetically engineered T
cells from 51 people
whose leukemia came back or who didn't respond to initial chemotherapy.
«CD22 CAR T -
cell immunotherapy trial open for children and young adults
whose leukemia escapes CD19 CAR T -
cell therapy.»
«These findings could lead to a new therapeutic strategy for patients with AML and potentially other diseases by targeting patients
whose leukemia cells display activation of a specific survival pathway.»
In addition to being integral to
cell biology, tyrosine kinases also present targets for new anticancer therapies: One of the most highly touted, rationally designed anticancer compounds, Gleevec, inhibits an oncogenic tyrosine kinase
whose aberrant activity fuels the rampant growth of
cells in patients with chronic myeloid
leukemia.
By developing a CAR T -
cell therapy that targets a second target on malignant
cells, it may help
leukemia patients
whose cancer
cells lack the C19 molecule or lose it.